Clinical Trials Logo

Filter by:
NCT ID: NCT05184101 Withdrawn - COVID-19 Clinical Trials

Inhaled Heparin for Hospitalised Patients With Coronavirus Disease 2019 (COVID-19)

INHALE-HEP
Start date: August 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Investigator-initiated, multi-centre, randomised, open-label trial of nebulised heparin sodium in addition to standard care compared to standard care alone in hospitalised patients with COVID-19 infection.

NCT ID: NCT05176691 Withdrawn - Follicular Lymphoma Clinical Trials

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

Start date: February 15, 2022
Phase: Phase 1
Study type: Interventional

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-760 in patients with previously treated CLL/SLL or NHL

NCT ID: NCT05152641 Withdrawn - Clinical trials for Acute Posthemorrhagic Anemia

Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery

Start date: April 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the safety and tolerability of BGE-117 and gain information on the effectiveness of different doses when given to patients 65 years or older with moderate to severe anemia following major hip surgery. BGE-117 is given once daily in a capsule by mouth for up to 12 weeks. Patients are also given oral iron supplements. Anemia following surgery has been associated with decreases in patient functioning. This study will measure improvement of anemia, as well as various patient functioning.

NCT ID: NCT05129306 Withdrawn - Allergic Rhinitis Clinical Trials

Impact of RYALTRIS® Nasal Spray on Patients' Reported Outcomes

Start date: November 17, 2021
Phase:
Study type: Observational

A real world evidence study that aims to understand the impact of RYALTRIS® nasal spray in patients with Allergic Rhinitis over a 28-day period.

NCT ID: NCT05095246 Withdrawn - Cystic Fibrosis Clinical Trials

A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis

Start date: March 8, 2022
Phase: Phase 1
Study type: Interventional

The Sponsor is developing KB407, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) to the airways of people with cystic fibrosis via nebulization. This study is designed to evaluate safety and tolerability of KB407 in people with cystic fibrosis. This study will enroll 4 participants into each of the first two cohorts and will enroll five subjects into the last cohort. Cohort 1 will receive a single dose of KB407 and be followed for 60 days. Subjects in Cohort 1 may rollover into Cohort 2 at the Day 28 Visit. A Data Safety Monitoring Board (DSMB) will meet to determine study progress from Cohort 2 into Cohort 3. In Cohort 2, subjects will be dosed bi-weekly at Day 0 and Day 14. In Cohort 3 subjects will be dosed weekly at Day 0, Day 7, Day 14 and Day 21. All subjects will be followed for a year after the last dose of KB407.

NCT ID: NCT05041114 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis

SWITCH II Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis

Start date: April 21, 2022
Phase: N/A
Study type: Interventional

The Synchron Motor Neuroprosthesis (MNP) is intended to be used in subjects with severe motor impairment, unresponsive to medical or rehabilitative therapy and a persistent functioning motor cortex. The purpose of this research is to evaluate safety and feasibility. The MNP is a type of implantable brain computer interface which bypasses dysfunctional motor neurons. The device is designed to restore the transmission of neural signal from the cerebral cortex utilized for neuromuscular control of digital devices, resulting in a successful execution of non-mechanical digital commands.

NCT ID: NCT05029856 Withdrawn - Covid19 Clinical Trials

Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults

Start date: February 4, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a randomized, observer-blinded, Phase 1/2 study with an open-label group to evaluate the safety and immunogenicity of 3 novel SARS-CoV-2 variant vaccine constructs adjuvanted with Matrix-M1 adjuvant. Investigational products will include a monovalent SII SARS-CoV-2 B.1.351 (Beta) variant vaccine (SII B.1.351), a bivalent SII vaccine containing antigen for both the ancestral strain and B.1.351 (Beta) variant of SARS-CoV-2 (SII Bivalent), and a monovalent SII SARS-CoV-2 B.1.617.2 (Delta) variant vaccine (SII B.1.617.2).

NCT ID: NCT04898348 Withdrawn - Ulcerative Colitis Clinical Trials

A Study to Investigate Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative Colitis

Start date: January 14, 2022
Phase: Phase 2
Study type: Interventional

The study is designed to investigate efficacy and safety of KBL697 in patients with mild to moderate active ulcerative colitis. KBL697 has been developed as a potential new treatment for ulcerative colitis.

NCT ID: NCT04891718 Withdrawn - Solid Tumour Clinical Trials

CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia

Start date: September 15, 2021
Phase: Early Phase 1
Study type: Interventional

This is a multi-center, open-label Phase 0 Master Protocol in Australia designed to study the localized pharmacodynamics (PD) of anti-cancer therapies within the tumour microenvironment (TME) when administered intratumourally in microdose quantities via the CIVO device in patients with surface accessible solid tumours for which there is a scheduled surgical intervention. CIVO stands for Comparative In Vivo Oncology. Multiple substudies will include specified investigational agents and combinations to be evaluated.

NCT ID: NCT04841512 Withdrawn - Clinical trials for Osteoarthritis, Spine

Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis

Start date: October 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Preliminary safety and efficacy of XT-150 in the synovial capsule of osteoarthritic facet joints in the vertebra of the spine.